Autoimmune Diseases  >>  Soliris (eculizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
NCT01275287: Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab

Withdrawn
2
0
US
Standard of care treatment, cytoxan, eculizumab, Soliris
University of North Carolina, Chapel Hill, Alexion Pharmaceuticals, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
12/12
12/12
DECADE, NCT01303952 / 2009-016966-97: Therapy of Chronic Cold Agglutinin Disease With Eculizumab

Completed
2
13
Europe
Eculizumab
University Hospital, Essen, Alexion Pharmaceuticals
Cold Agglutinin Disease
09/14
06/15
NCT00904826: An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica

Checkmark Relapsing NMOSD POC trial
Dec 2015 - Dec 2015: Relapsing NMOSD POC trial
Completed
1/2
14
US
Eculizumab, Soliris
Mayo Clinic, Alexion Pharmaceuticals
Neuromyelitis Optica, Devic's Disease
12/11
12/11

Download Options